Cargando…

Novel Carboxypeptidase A6 (CPA6) Mutations Identified in Patients with Juvenile Myoclonic and Generalized Epilepsy

Carboxypeptidase A6 (CPA6) is a peptidase that removes C-terminal hydrophobic amino acids from peptides and proteins. The CPA6 gene is expressed in the brains of humans and animals, with high levels of expression during development. It is translated with a prodomain (as proCPA6), which is removed be...

Descripción completa

Detalles Bibliográficos
Autores principales: Sapio, Matthew R., Vessaz, Monique, Thomas, Pierre, Genton, Pierre, Fricker, Lloyd D., Salzmann, Annick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395397/
https://www.ncbi.nlm.nih.gov/pubmed/25875328
http://dx.doi.org/10.1371/journal.pone.0123180
_version_ 1782366440768143360
author Sapio, Matthew R.
Vessaz, Monique
Thomas, Pierre
Genton, Pierre
Fricker, Lloyd D.
Salzmann, Annick
author_facet Sapio, Matthew R.
Vessaz, Monique
Thomas, Pierre
Genton, Pierre
Fricker, Lloyd D.
Salzmann, Annick
author_sort Sapio, Matthew R.
collection PubMed
description Carboxypeptidase A6 (CPA6) is a peptidase that removes C-terminal hydrophobic amino acids from peptides and proteins. The CPA6 gene is expressed in the brains of humans and animals, with high levels of expression during development. It is translated with a prodomain (as proCPA6), which is removed before secretion. The active form of CPA6 binds tightly to the extracellular matrix (ECM) where it is thought to function in the processing of peptides and proteins. Mutations in the CPA6 gene have been identified in patients with temporal lobe epilepsy and febrile seizures. In the present study, we screened for CPA6 mutations in patients with juvenile myoclonic epilepsy and identified two novel missense mutations: Arg36His and Asn271Ser. Patients harboring these mutations also presented with generalized epilepsy. Neither of the novel mutations was found in a control population. Asn271 is highly conserved in CPA6 and other related metallocarboxypeptidases. Arg36 is present in the prodomain and is not highly conserved. To assess structural consequences of the amino acid substitutions, both mutants were modeled within the predicted structure of the enzyme. To examine the effects of these mutations on enzyme expression and activity, we expressed the mutated enzymes in human embryonic kidney 293T cells. These analyses revealed that Asn271Ser abolished enzymatic activity, while Arg36His led to a ~50% reduction in CPA6 levels in the ECM. Pulse-chase using radio-labeled amino acids was performed to follow secretion. Newly-synthesized CPA6 appeared in the ECM with peak levels between 2-8 hours. There was no major difference in time course between wild-type and mutant forms, although the amount of radiolabeled CPA6 in the ECM was lower for the mutants. Our experiments demonstrate that these mutations in CPA6 are deleterious and provide further evidence for the involvement of CPA6 mutations in the predisposition for several types of epilepsy.
format Online
Article
Text
id pubmed-4395397
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43953972015-04-21 Novel Carboxypeptidase A6 (CPA6) Mutations Identified in Patients with Juvenile Myoclonic and Generalized Epilepsy Sapio, Matthew R. Vessaz, Monique Thomas, Pierre Genton, Pierre Fricker, Lloyd D. Salzmann, Annick PLoS One Research Article Carboxypeptidase A6 (CPA6) is a peptidase that removes C-terminal hydrophobic amino acids from peptides and proteins. The CPA6 gene is expressed in the brains of humans and animals, with high levels of expression during development. It is translated with a prodomain (as proCPA6), which is removed before secretion. The active form of CPA6 binds tightly to the extracellular matrix (ECM) where it is thought to function in the processing of peptides and proteins. Mutations in the CPA6 gene have been identified in patients with temporal lobe epilepsy and febrile seizures. In the present study, we screened for CPA6 mutations in patients with juvenile myoclonic epilepsy and identified two novel missense mutations: Arg36His and Asn271Ser. Patients harboring these mutations also presented with generalized epilepsy. Neither of the novel mutations was found in a control population. Asn271 is highly conserved in CPA6 and other related metallocarboxypeptidases. Arg36 is present in the prodomain and is not highly conserved. To assess structural consequences of the amino acid substitutions, both mutants were modeled within the predicted structure of the enzyme. To examine the effects of these mutations on enzyme expression and activity, we expressed the mutated enzymes in human embryonic kidney 293T cells. These analyses revealed that Asn271Ser abolished enzymatic activity, while Arg36His led to a ~50% reduction in CPA6 levels in the ECM. Pulse-chase using radio-labeled amino acids was performed to follow secretion. Newly-synthesized CPA6 appeared in the ECM with peak levels between 2-8 hours. There was no major difference in time course between wild-type and mutant forms, although the amount of radiolabeled CPA6 in the ECM was lower for the mutants. Our experiments demonstrate that these mutations in CPA6 are deleterious and provide further evidence for the involvement of CPA6 mutations in the predisposition for several types of epilepsy. Public Library of Science 2015-04-13 /pmc/articles/PMC4395397/ /pubmed/25875328 http://dx.doi.org/10.1371/journal.pone.0123180 Text en © 2015 Sapio et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sapio, Matthew R.
Vessaz, Monique
Thomas, Pierre
Genton, Pierre
Fricker, Lloyd D.
Salzmann, Annick
Novel Carboxypeptidase A6 (CPA6) Mutations Identified in Patients with Juvenile Myoclonic and Generalized Epilepsy
title Novel Carboxypeptidase A6 (CPA6) Mutations Identified in Patients with Juvenile Myoclonic and Generalized Epilepsy
title_full Novel Carboxypeptidase A6 (CPA6) Mutations Identified in Patients with Juvenile Myoclonic and Generalized Epilepsy
title_fullStr Novel Carboxypeptidase A6 (CPA6) Mutations Identified in Patients with Juvenile Myoclonic and Generalized Epilepsy
title_full_unstemmed Novel Carboxypeptidase A6 (CPA6) Mutations Identified in Patients with Juvenile Myoclonic and Generalized Epilepsy
title_short Novel Carboxypeptidase A6 (CPA6) Mutations Identified in Patients with Juvenile Myoclonic and Generalized Epilepsy
title_sort novel carboxypeptidase a6 (cpa6) mutations identified in patients with juvenile myoclonic and generalized epilepsy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395397/
https://www.ncbi.nlm.nih.gov/pubmed/25875328
http://dx.doi.org/10.1371/journal.pone.0123180
work_keys_str_mv AT sapiomatthewr novelcarboxypeptidasea6cpa6mutationsidentifiedinpatientswithjuvenilemyoclonicandgeneralizedepilepsy
AT vessazmonique novelcarboxypeptidasea6cpa6mutationsidentifiedinpatientswithjuvenilemyoclonicandgeneralizedepilepsy
AT thomaspierre novelcarboxypeptidasea6cpa6mutationsidentifiedinpatientswithjuvenilemyoclonicandgeneralizedepilepsy
AT gentonpierre novelcarboxypeptidasea6cpa6mutationsidentifiedinpatientswithjuvenilemyoclonicandgeneralizedepilepsy
AT frickerlloydd novelcarboxypeptidasea6cpa6mutationsidentifiedinpatientswithjuvenilemyoclonicandgeneralizedepilepsy
AT salzmannannick novelcarboxypeptidasea6cpa6mutationsidentifiedinpatientswithjuvenilemyoclonicandgeneralizedepilepsy